RI

REGENT Craft Announces Strategic Investment from H.I.S.

Retrieved on: 
Thursday, March 7, 2024

North Kingstown, RI, March 07, 2024 (GLOBE NEWSWIRE) -- REGENT, the manufacturer of all-electric seagliders for sustainable maritime mobility, today announced a strategic investment from H.I.S.

Key Points: 
  • North Kingstown, RI, March 07, 2024 (GLOBE NEWSWIRE) -- REGENT, the manufacturer of all-electric seagliders for sustainable maritime mobility, today announced a strategic investment from H.I.S.
  • This investment marks a significant step forward in advancing sustainable travel and enhancing regional travel experiences for customers in Japan and beyond.
  • REGENT seagliders are a hydrofoiling wing-in-ground effect craft that operate exclusively over water.
  • They represent a new category of maritime vessel combining the high speed of an airplane with the low operating cost of a boat.

Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting

Retrieved on: 
Thursday, February 29, 2024

The late breaker presentation will highlight the safety data observed, to date, in the ongoing Phase 1B clinical trial of VRON-0200.

Key Points: 
  • The late breaker presentation will highlight the safety data observed, to date, in the ongoing Phase 1B clinical trial of VRON-0200.
  • “This accepted abstract highlights Virion’s commitment to finding a functional cure for chronically HBV-infected patients - and the first-ever human data for a genetically encoded checkpoint modifier T cell vaccine of any kind.
  • VRON-0200 is uniquely developed to stimulate a patient’s own immune response to the virus.
  • Department of Medicine and Therapeutics, and Institute of Digestive Disease, Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong

DiagnaMed Announces Test Launch of CERVAI™ Brain Health in University Brain Health Center

Retrieved on: 
Wednesday, February 28, 2024

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health, today announced a test launch of CERVAI™, a world-first consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health.

Key Points: 
  • TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health, today announced a test launch of CERVAI™, a world-first consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health.
  • The initial focus will be evaluating the brain health assessment portion of CERVAI™, which scores brain health by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.
  • Essentially, it is intended to “take a snapshot” of a patient’s brain health.
  • The CERVAI™ Brain Health test pilot program continues to be open to a select 25 clinics in the U.S. and Canada.

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on: 
Tuesday, March 12, 2024

16

Key Points: 
    • 16

      Guideline on allergen products development for
      immunotherapy and allergy diagnosis in moderate to lowsized study populations

      17

      Table of contents

      18

      Executive summary ..................................................................................... 3

      19

      1.

    • Specific effects ................................................................................................. 17

      14
      15

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 2/18

      53

      12.

    • Management for allergies may involve avoidance of the allergen, medications to relieve

      66

      symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.

    • 71

      Recommendations are made on the clinical development, potential study designs and safety

      72

      considerations for allergen products within the scope of the guideline.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 3/18

      88

      While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

      89

      there is no such treatment available for type IV allergies.

    • 93

      Several guidelines applicable for allergen products are available (see section 3) and provide advice on

      94

      quality and clinical development according to the current knowledge.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 4/18

      127

      However, this guideline does not cover the indication of atopic dermatitis or asthma as these

      128

      conditions will require separate clinical trials (see Section 6).

    • 129

      In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

      130

      DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

      131

      substantially to the allergen products as discussed above.

    • 1

      156

      ?

      Guideline on the clinical development of products for specific immunotherapy for the treatment

      157
      158

      of allergic diseases - CHMP/EWP/18504/2006
      ?

      159
      160
      161

      Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

      ?

      Guideline on process validation for finished products - information and data to be provided in
      regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 5/18

      162

      ?

      Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

      163

      4.

    • In any

      199

      case, a reduced validation should include all relevant manufacturing process steps that are considered
      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 6/18

      200

      product specific.

    • 290

      Diagnostic allergen products (Type I allergy)

      291

      A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

      292

      intracutaneous or provocation testing.

    • 298

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 9/18

      305
      306

      7.1.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 11/18

      377

      8.

    • Clinical development of products for AIT: Study design,
      efficacy and safety

      378

      In general, the clinical development should be performed according to current guidelines.

    • In such single trial, the suitability as a test allergen as well as the

      376

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 12/18

      415

      dose finding for the therapeutic allergen could be investigated.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 13/18

      454
      455

      8.2.1.

    • 493

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 15/18

      527

      In general, sensitivity and specificity of the product should be determined.

    • 540

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 16/18

      561

      10.2.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 17/18

      595

      4.

    • Allergol Immunopathol, 1989;

      602

      17(2):53-65

      603

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 18/18

University of Phoenix Leadership Joins 2024 SXSW EDU Panel on Non-Traditional Learners

Retrieved on: 
Friday, March 8, 2024

University of Phoenix is pleased to share that Nathan Jones, vice president of Product for Workforce Solutions, joined the proceedings of SXSW EDU, March 4 - 7, 2024, in Austin, Texas.

Key Points: 
  • University of Phoenix is pleased to share that Nathan Jones, vice president of Product for Workforce Solutions, joined the proceedings of SXSW EDU, March 4 - 7, 2024, in Austin, Texas.
  • “At University of Phoenix, our focus is on leveraging automation and technology to create a more personalized student experience.
  • As a recovering society, the reality of how to bring back a “lost generation” of learners requires coordination across sectors.
  • In his more than 19 years with University of Phoenix, he has held leadership roles in Employee Development, Enrollment Management, Academic Operations, Product Leadership, and Workforce Solutions.

PEPSICO CAMPAIGN INSPIRES AND CELEBRATES WOMEN THRIVING IN SUPPLY CHAIN CAREERS

Retrieved on: 
Thursday, February 29, 2024

PURCHASE, N.Y., Feb. 29, 2024 /PRNewswire/ -- PepsiCo today announced the global She is PepsiCo campaign, which will include recognition of women who work in frontline roles in markets around the world, showcasing their transformative abilities, and helping to recruit even more to apply for frontline roles. The annual program rebrands some of the company's highly visible delivery trucks with the names and faces of She is PepsiCo honorees. Featuring photos of these employees in their work settings, in place of the company's brands, is at the heart of how the global campaign aims to celebrate and empower women.

Key Points: 
  • A 2023 Gartner survey showed that women made up 41% of the total supply chain workforce, up from 39% in 2022.
  • The She is PepsiCo campaign demonstrates how women can build and grow a meaningful frontline career at PepsiCo supported by the tools and culture to nurture their continued development.
  • "PepsiCo wants women to clearly see the career opportunities that are available to them and hear from the women who are thriving in frontline careers, and beyond.
  • Karen Jordan is the Chief Supply Chain Officer for PBNA, and Laura Maxwell is the Chief Supply Chain Officer for PepsiCo Foods North America (PFNA).

ESS Laboratory Certified by RI Health Department to Perform PFAS Drinking Water Testing

Retrieved on: 
Monday, February 26, 2024

CRANSTON, R.I., Feb. 26, 2024 /PRNewswire/ -- In response to growing health concerns, ESS Laboratory announces it has been certified by the Rhode Island Department of Health to begin offering comprehensive drinking water testing for per- and poly-fluoroalkyl substances, commonly called "PFAS".

Key Points: 
  • CRANSTON, R.I., Feb. 26, 2024 /PRNewswire/ -- In response to growing health concerns, ESS Laboratory announces it has been certified by the Rhode Island Department of Health to begin offering comprehensive drinking water testing for per- and poly-fluoroalkyl substances, commonly called "PFAS".
  • Drinking water samples will now be extracted and analyzed in the ESS Cranston, RI laboratory.
  • PFAS are found in a wide range of consumer products such as cookware, pizza boxes, and stain.
  • ESS has deployed state-of-the-industry equipment that allows detection of PFAS compounds with exceptional sensitivity at the parts per trillion level.

InsureMyTrip Names Suzanne Morrow as Chief Executive Officer

Retrieved on: 
Thursday, February 15, 2024

Toronto, Feb. 15, 2024 (GLOBE NEWSWIRE) -- InsureMyTrip , Canada's rapidly growing travel insurance comparison website, announces Suzanne Morrow as the company’s Chief Executive Officer.

Key Points: 
  • Toronto, Feb. 15, 2024 (GLOBE NEWSWIRE) -- InsureMyTrip , Canada's rapidly growing travel insurance comparison website, announces Suzanne Morrow as the company’s Chief Executive Officer.
  • Since joining InsureMyTrip in 2016, Morrow has played a crucial role in the company's overall growth and international expansion.
  • "I'm honoured for this opportunity to lead InsureMyTrip into the next phase of its history," said Morrow.
  • Before coming to InsureMyTrip, Morrow held several leadership positions and is a retired Captain from the United States Air Force.

BUILDING HOPE ANNOUNCES SIX FINALISTS FOR 2024 SHELLIE-ANN BRASWELL 'SHINE BRIGHTER' IMPACT AWARD

Retrieved on: 
Wednesday, February 14, 2024

WASHINGTON, Feb. 14, 2024 /PRNewswire/ -- Building Hope, the non-profit leader in charter school facilities, financing, and services, today announced six finalists for its third annual Shellie-Ann Braswell Shine Brighter Award. The award – created and named in honor of dedicated volunteer leader Shellie-Ann Braswell who led with love and made everything around her shine brighter – recognizes exceptional charter school volunteer dedication and leadership.

Key Points: 
  • Charter School Volunteers Recognized For Their Exceptional Dedication and Leadership; Vie for $5,000 Award
    WASHINGTON, Feb. 14, 2024 /PRNewswire/ -- Building Hope , the non-profit leader in charter school facilities, financing, and services, today announced six finalists for its third annual Shellie-Ann Braswell Shine Brighter Award.
  • The award – created and named in honor of dedicated volunteer leader Shellie-Ann Braswell who led with love and made everything around her shine brighter – recognizes exceptional charter school volunteer dedication and leadership.
  • "It is an honor to recognize these amazing volunteer leaders who are the heartbeat of their charter schools," said Allie L. Braswell, Jr., CEO of The Braswell Group.
  • The gift of their time and effort is a profound act of love," shared Sherilyn Moore, Building Hope's Chief IMPACT Officer and Chair of the IMPACT Selection Committee.

KVH Announces Transformative Initiatives

Retrieved on: 
Tuesday, February 13, 2024

MIDDLETOWN, R.I., Feb. 13, 2024 (GLOBE NEWSWIRE) -- KVH Industries, Inc. (“KVH” or the “Company”) (Nasdaq: KVHI), today announced plans to wind down its hardware manufacturing operations to focus on strengthening its position as a streamlined provider of multi-orbit, multi-channel, integrated communications solutions. This development follows the Company’s recently announced additions of Starlink and Eutelsat OneWeb to its connectivity portfolio and its exclusive maritime agreement with Kognitive Networks. The Company also announced changes to its management team.

Key Points: 
  • David Tolley, Chairman of KVH, commented, “Today’s announcement is the culmination of the Board’s extensive examination for how to best position KVH for the future as our markets continue to evolve.
  • During this process, KVH plans to manufacture enough maritime satellite connectivity and satellite television terminals needed to meet demand for the foreseeable future.
  • KVH will continue to conduct its equipment repair and refurbishments, warehousing and shipping and receiving activities at the Middletown, Rhode Island location.
  • KVH expects to release earnings and host a conference call in early March to discuss the Company’s ongoing strategic evolution along with fourth quarter and full-year 2023 results.